1. The -galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain
2. Demotte, N. Wieers, G. Klyosov, A. van der Bruggen, P. Is it possible to correct the impaired function of human tumor-infiltrating lymphocytes? Presented at Keystone Symposium on Molecular and Cellular Biology. New Frontiers at the Interface of Immunity and Glycobiology; March 6−11, 2011; Lake Louise, AB, Canada; Abstract 23F11.
3. The World Almanac and Book of Facts;2010; p. 155.
4. Some Antineoplastic and Immunosuppressive Agents. WHO, International Agency for Research on Cancer.IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans;1981;Vol. 26, pp 217− 235.
5. Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation; Advances in Experimental Medicine and Biolology Series; Rustum, Y. M. , Ed.Plenum Press:1994; Vol.339, p319.